Mangalam Drugs & Organics Limited (Mangalam) is a part of the Mangalam Group, promoted by Dhoot family in 1972 as Advent Pharma Private Limited with a view to set up a plant for manufacture of organic and inorganic chemicals. On April 1, 1996 three other group companies i.e. Mangalam Organics Private Limited, Shree Mangalam Pharma Private Limited and Mangalam Rasayan Private Limited were merged with Advent Pharma Private Limited. Under the scheme of arrangement approved by the Honorable High Court, Mumbai and Gujarat, the entire chemical division of MOPL, MRPL and SMPPL was transferred to and vested in MDOL as a going concern free from all encumbrances and on that basis MDOL issued one fully paid equity share of MDOL for every twenty fully paid equity shares of MOPL, twelve fully paid equity shares of MDOL for every five fully paid equity shares of MRPL and twenty-seven fully paid equity shares of MDOL for every five fully paid equity shares of SMPPL to the share holders of MOPL, MRPL and SMPPL respectively. Subsequent to this merger, the name of Advent Pharma Private Limited was changed to Mangalam Drugs and Organics Private Limited. In September 1997, it became a deemed public limited company in terms of Section 43A of the Companies Act, 1956. In 2001, the company was converted into a full fledged public limited company in terms of Special Resolution passed on August 10th, 2001. The company has a state of art multi-product manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra for production of bulk drugs, perfumery chemicals, inorganic chemicals and disperse dyes intermediaries with a strong in-house Research and Development base. MDOL is an ISO 9001 certified company, with a WHO GMP Certificate (since expired, has applied for renewal) for its bulk drugs manufacturing plant, implying that the company carries out good manufacturing practices, which is an important tool for promoting its exports. It enjoys a strong brand name in the domestic market with over three decades of experience in the industry with a wide and satisfied customer base. Company's manufacturing facility at Plot No. 187, Vapi has received Certification of Suitability dated 27th September 2004, from European Directorate for the Quality of Medicine (EDQM) for the production of an existing product, Nimesulide. In the year 2003-2004, the bulk drug production capacity of the Company was increased from 350 MTPA to 600 MTPA. During the current year, the capacity is being further enhanced to 960 MTPA.Presently various bulk drugs, other drug intermediates and specialty chemicals such as Nimesulide, 4-M.E.P., Oranger Crystals and DTDBA are being produced in the production facilities The cost pf expansion of capacity is Rs.975 lacs and the same would be financed through internal accruals/unsecured loans from promoters to the tune of Rs.325 lacs and balance amount of Rs.650 lacs being financed by Term Loan from State Bank of India. The said term loan has been sanctioned by SBI and the company has commenced drawal of funds. The company with its proven R & D process, has the ability to improve processes through process innovation, enhance process yields, thereby reduce costs, coupled with flexible production process, places it in a position of strength to cater to the requirement of its customers under one roof. Thus, the company has been able to carve a place for itself in the segments it is operating in. There exists an extremely good market for Anti-Malarial Drugs and Aluminium Chloride being produced by the company. It intends to take advantage of the estimated demand supply gap in the market and capitalize on its present strengths in quality, experience and reputation. The Company has a stable and well-established customer base and flexible distribution network for its products. Recently, the Government of India has imposed an anti-dumping duty on import of Chloroquine Phosphate vide their Notification No. 14/3/2003- DGAD dated 15th July, 2004, which is likely to result in a major surge in demand for the product in the local market. Vision, Mission, Quality Policy & Core Values: Vision: * To Be a well respected company in the businesses and geographies we operate in and * To Become an admired bulk - drugs (API) manufacturing company with strong focus on research. Mission: To achieve growth in business by * Attaining globally competitive cost levels * Enhancing the value we deliver to stakeholders * Commitments to corporate responsibility Employees are our strength and we will create an environment that fosters achievement, innovation and teamwork. Quality Policy: Mangalam is committed to customer satisfaction by offering quality products and services meeting their specifications and expectations at competitive prices by customer - employee - vendor in involvement and adopting GOOD MANUFACTURING PRACTICES AND QUALITY MANAGEMENT SYSTEMS. It aims to create and maintain safe and healthy working conditions, protect the environment, strive for continual improvement of our personnel, quality and processes of products and meet regulatory requirements. Core Values: * Excellence * Innovation * Fairness * Transparency * Encouraging Initiative Key Strengths: * Existing company with three decades of experience and expertise in its field * An established brand name * In-house manufacturing facilities with the state of art process, quality control and R & D * Availability of Pilot Plant * Proven leadership * Extensive Marketing network in India and abroad * Proven R&D capabilities to develop efficient and cost effective process * ISO 9001 certification and WHO-GMP* Certification for CQP Plant at the Vapi facility * Certification of Suitability from European Directorate for the Quality of Medicine (EDQM) for the production of an existing product, Nimesulide * WHO GMP Certificate has expired and the company has applied for renewal of the same. PRODUCTS AND SERVICES Products Manufactured by the company are: BULK DRUGS & INTERMEDIATES A] ANTIMALARIAL CHLOROQUINE PHOSPHATE I.P./B.P. CHLOROQUINE SULPHATE I.P./B.P. AMODIAQUINE HCL USP/IP AMODIAQUINE BASE USP B] ANTIANALGESIC NIMESULIDE E.P./B.P. C] INTERMEDIATES 4, 7, DICHLORO QUINOLINE 4 METHOXY ETHYL PHENOL META CHLORO ANILINE SUCCINIMIDE ORTHO PHENOXY ANILINE ORTHO PHENOXY METHANE SULFONYL ANILIDE 3, 4 DICHLORO NITROBENZENE ORTHO METHOXY TOLUENE 4 (2-AMINOETHYL) MORPHOLINE PHENYL ETHYL CHLORIDE INORGANIC/ORGANIC CHEMICALS ALUMINIUM CHLORIDE (ANHYDROUS) PHENOXY ETHANOL PERFUMERY CHEMICALS PHENYL ETHYL ALCOHOL PHENYL ETHYL METHYL ETHER PHENYL ETHYL ACETATE ORANGER CRYSTALS (METHYL BETA NAPHTHYL KETONE) SPECIALITY CHEMICALS N.N-BIS (2-HYDROXY ETHYL) META TOLUIDINE. (MANGALAM-2) N-ETHYL-N-HYDROXY ETHYL-ANILINE. (MANGALAM-15) N-HYDROXY ETHYL-N-ETHYL META TOLUIDINE (MANGALAM-21) N.N.BIS (2-HYDROXY ETHYL) -PARA TOLUIDINE (MANGALAM-25) N.N-BIS (2-HYDROXY PROPYL)-PARA TOLUIDINE. (MANGALAM-26) DISPERSE DYE INTERMEDIATES BY PRODUCTS ALUMINIUM CHLORIDE (SOLUTION) TRISODIUM PHOSPHATE SODIUM THIO SULPHATE PRODUCTS UNDER DEVELOPMENT TRICLOSAN TRICLORO CARBANILIDE AVO BENZONE OCTYL METHOXY CINNAMATE 4 HYDROXY PHENYL ETHYL ALCOHOL META HYDROXY ACETOPHENONE ARTISUNATE ARTIMETER ARTIETHER The company is supplying its products to Indoco Remedies Ltd..Nicholas Piramal India Ltd, May (India) Laboratories Ltd, Bayer Pharmaceuticals, Unicure (India) P. Ltd, Cipla The Karnataka state Agarbatthi etc.,to name a few. Key milestones Key milestones of Mangalam over the years are set out below: Year Milestone 1977 First plant for Manufacture of perfumery chemicals at Plot No. 187, GIDC, Vapi was started under the name "Advent Pharma Pvt. Ltd." (APPL) 1981 A new plant under the name "Mangalam Rasayan Pvt. Ltd." (MRPL) was commissioned for manufacture of Anhydrous Aluminium Chloride 1984 A new plant was commissioned under the name "Shree Mangalam Pharma Pvt. Ltd." (SMPPL) where higher manufacturing capacity of Aromatic Chemicals was created. 1984 The facilities in APPL was re-organised to manufacture the first "Bulk Drug" in the group namely "Metronidazole I. P." 1985 The capacity of Anhydrous Aluminium Chloride was doubled 1987 Inorganic chemicals manufacturing capacities were expanded by putting up a new plant at Sangamner under the name "Mangalam Inorganics Pvt. Ltd." (MIPL) 1989 A new plant was erected to manufacture Dyes Intermediates at Plot No. 1203, IIIrd Phase, GIDC, Vapi under the name Mangalam Organics Private Ltd. (MOPL) 1991 Additional manufacturing capacity for perfumery chemicals was created under new plant of SMPPL 1994 A New Plant was commissioned for manufacturing of Meta Chloro Aniline under MRPL 1997 Scheme of arrangement between SMPPL, MOPL and MRPL by transferring their entire Chemical Division to Mangalam Drugs & Organics Ltd. 1999 A new product namely "Nimesulide" was launched from Plant at Plot No. 1203. 2001 Two new products namely Amodiaquine Hydrochloride and Amodiaquine were launched from Plant at Plot No.1203. 2002 WHO-GMP approval for Chloroquine Phosphate I.P./B.P. 2002 Awarded ISO-9000-2000 Management System Certificate from DNV. 2003 WHO-GMP approval for Amodiaquine Hydochloride and Amodiaquine U.S.P. 2003 -Awarded ISO-9000-2000 Management System Certificate from DNV. 2005 - Mangalam Drugs and Organics Ltd (MDOL) files prospectus with Securities Exchange Board of India to raise Rs 14.3 crore through a public issue to fund its expansion plans and support its growth in the anti-malarial segment. The offer is for 65,00,000 shares of Rs 10 each at a price of Rs 22 and will remain open from April 19 to April 26. - Shares of Mangalam Drugs & Organics Ltd made their debut on the Bombay Stock Exchange at Rs 30, higher than the issue price of Rs 22 on May 23. 2006 -The Company has recommended a Final Dividend of Re 0.20 ps (2%) per Equity Share 2009 - Mangalam Drugs & Organics Ltd appointed Mr. Mukul Sukhani has been appointed as Additional Director on the Board of the Company. 2014 -Mrs Meenal Sukhani has been appointed as Additional Director on the Board of the Company. -The registered office of the company has been shifted from Princess Street Near Flyover Bridge, Marine Lines, Mumbai to P.D. Mello Road, Mumbai- 400 020 to '3rd Floor, Rupam Building, 237, P. D. Mello Road, Mumbai - 400001, Mahrashtra.